SEC Filing Details

We are a clinical-stage biopharmaceutical company leveraging our proprietary next-generation, non-viral gene engineering technologies to create life-saving cell and gene therapies for patients with high unmet medical need.

SEC Filing Details

Document Details

Form
Filing Date
Jan 10, 2022
Document Date
Jan 8, 2022
Form Description
Report of unscheduled material events or corporate event
Filing Group
Current Reports
Company
Poseida Therapeutics, Inc.
Issuer
Poseida Therapeutics, Inc.